2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, LGL, Hodgkin Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4348 Integrated whole-blood DNA and RNA sequencing for myeloid malignancies: Development of a multimodal hybrid-capture panel

Simon Michael Hughes, PhD, Gavin Batman2, Maisie Berry3, Jacob Chapman4, Jeannine Clancy5, Susan Felton-smith6, Alice Fiil7, Michael Gombert8, Nadia Goncalves9, Vikas Gupta, PhD10, John Paul Kennedy11, Chien Wen Phong12, Juergen Lauber, PhD13, Bethanie Neale14, Maria Orthodoxou15, John Rutter16, Nancy Schubert17, David Sutton18, Alexi Thorpe19, Paulina Tobiasz20
1 QIAGEN Manchester Ltd, Manchester, United Kingdom
2 QIAGEN Manchester Ltd, Manchester, United Kingdom
3 QIAGEN Manchester Ltd, Manchester, United Kingdom
4 QIAGEN Manchester Ltd, Manchester, United Kingdom
5 QIAGEN Manchester Ltd, Manchester, United Kingdom
6 QIAGEN Manchester Ltd, Manchester, United Kingdom
7 QIAGEN Aarhus, Aarhus, Denmark
8 QIAGEN Hilden, Hilden, Germany
9 QIAGEN Manchester Ltd, Manchester, United Kingdom
10 QIAGEN Aarhus, Aarhus, Denmark
11 QIAGEN Manchester Ltd, Manchester, United Kingdom
12 QIAGEN Manchester Ltd, Manchester, United Kingdom
13 QIAGEN Hilden, Hilden, Germany
14 QIAGEN Manchester Ltd, Manchester, United Kingdom
15 QIAGEN Manchester Ltd, Manchester, United Kingdom
16 QIAGEN Manchester Ltd, Manchester, United Kingdom
17 QIAGEN Hilden, Hilden, Germany
18 QIAGEN Manchester Ltd, Manchester, United Kingdom
19 QIAGEN Manchester Ltd, Manchester, United Kingdom
20 QIAGEN Manchester Ltd, Manchester, United Kingdom

Background: Comprehensive tumor profiling of myeloid malignancies requires concurrent detection of sequence variants and gene fusions. Conventional testing typically separates DNA and RNA workflows, requiring increased sample input. The QIAGEN HemeOnc NGS Panel for research use only, a multimodal DNA/RNA hybrid-capture assay for molecular research of myeloid malignancies from whole blood, enables streamlined detection of disease-relevant DNA variants (e.g., JAK2, CALR) and RNA fusions such as BCR‑ABL. This study evaluates the performance of this integrated workflow for simultaneous DNA variant and RNA fusion detection from a range of sample types.

Methods: Target selection (based on international guidelines) included 52 DNA and >100 RNA targets spanning disease-relevant mutations, prognostic markers and fusions. Probe design, hybrid-capture conditions and bioinformatic analysis were optimised to address technically challenging regions, including CALR exon 9, which contains heterogeneous insertion/deletion architectures. The workflow was configured for combined analysis of DNA and RNA extracted from a single whole-blood specimen. Library preparation incorporated unique molecular identifiers to reduce sequencing artefacts. Development used reference standards, cell lines, commercially acquired whole blood from samples representing myeloid disease subtypes (MPN and CML) (n=60) and whole blood from healthy volunteers (n=10). Performance was assessed for variant and fusion detection, concordance with orthogonal methods (e.g., ipsogen® CALR RGQ PCR Kit, ipsogen JAK2 RGQ PCR Kit and an in-house developed digital PCR assay for CALR indels), and consistency across multiple operators, library preparation, and sequencing runs. Bioinformatic analysis used an assay-specific pipeline with alignment and calling settings designed for complex variant detection, including indel-guided local realignment and breakpoint-sensitive calling.

Results: Accurate and reproducible detection of both DNA variants and RNA fusions was demonstrated across reference materials, cell lines and whole-blood specimens. All targeted DNA variants in reference materials and characterized cell lines showed 100% agreement between replicates, including CALR exon 9 deletions, JAK2 (p.V617F), MPL (p.W515L) and FLT3 internal tandem duplications. RNA fusions, including BCR-ABL, were consistently detected across reference materials and cell lines, as well as for commercially acquired whole blood from myeloid patient samples (n=20 fusion positive samples). Whole-blood samples from healthy volunteers were negative for all targets assessed, with no false-positive calls observed, supporting assay specificity. Optimization of DNA:RNA input ratio enabled balanced assay performance without loss of DNA variant or RNA fusion detection. In commercially acquired whole blood from myeloid patient samples, disease-associated DNA variants including JAK2 (n=28), CALR (n=5) and BCR-ABL (n=20) were reproducibly detected and were concordant with the orthogonal methods tested. Biological and technical replicate testing showed concordant variant calls across operators, library preparation batches, and sequencing runs, supporting reproducible assay performance under routine laboratory conditions.

Conclusions: The QIAGEN HemeOnc  NGS Panel for research use only enables integrated DNA and RNA research from whole blood within a single workflow. In development, the research assay demonstrated accurate detection of DNA variants and RNA fusions associated with myeloid malignancies, including technically challenging CALR exon 9 indels and BCR-ABL. These data support the use of a multimodal, variant-aware NGS approach for molecular assessment across myeloid malignancies while reducing sample input and consolidating research testing.

Simon Michael Hughes, PhD: QIAGEN Manchester Ltd - Stock (publicly traded); QIAGEN Manchester Ltd - Current Employment